Monocyte Chemoattractant Protein-1 (MCP-1), Chemokine Receptor2 Gene Polymorphism and Level of MCP-1 in Behcet's Disease: A Case-Control Study

HEBA M. SELIM, M.D., AMAL H. EISSA, M.D.;; KARAM K. NAGUIB, M.D., HUSSEIN S. EL-FISHAWY, M.D.;; ABEER M. ZAHRAN, M.D., MOHAMED S. TAWFIK, M.D.;

doi:10.21608/mjcu.2022.286947

Monocyte Chemoattractant Protein-1 (MCP-1), Chemokine Receptor2 Gene Polymorphism and Level of MCP-1 in Behcet's Disease: A Case-Control Study

Document Type : Original Article

Authors

The Department of Clinical Pathology1, Faculty of Medicine, Helwan University, Clinical & Chemical Pathology Department2, Faculty of Medicine, Cairo University, Internal Medicine Department3, Faculty of Medicine, Cairo Universi Giza, Egypt, Ophthalmology Department4, Nasser Institute Hospital, Giza, Egypt, Health Radiation Research Department5"National Centre for Radiation Research & Tecgnology, Egyptian Atomic Energy Authority, Cairo, Egypt and Rheumatology & Rehabilitation Department6, Faculty of Medicine, Cairo University

10.21608/mjcu.2022.286947

Abstract

Abstract Bachground: Behcet’s disease (BD) is chronic autoimmune vasculitic disease, its pathogenesis still unclear, it could be a combination of environmental and genetic factors. Both MCP-1 and its receptor CCR2 have been incriminated in the pathogenesis of multiple inflammatory disorders. Aim of Study: The aim of this study wasto investigate the potential associationof serum of monocyte chemoattractant protein-1 (MCP-1), genetic derangement of MCP-1 and chem-okine receptor2 (CCR2) with Behcet's disease. Patients and Methods: Thirty BD patients' blood samples were gathered and 30 healthy subjects with matching age and sexa, were tested for blood MCP-1 using Enzyme linked Immunosorbant assay (ELISA), MCP-1 c. 2518A/G and CCR2 -V641 polymorphism as determined by polymerase chain reaction (PCR). Assessment of disease activity was done using Behcet's Disease Current Activity Form (BDCAF). Results: The studied patients mean age was 34.9±12.2 years, mean age of disease onset was 26.7±8.8 years and mean disease duration 6.9±7.3 years. Blood levels of MCP-1 in BD patients was 241.7±179.45mg/l versus 23.1±27.06mg/l in healthy subjects and the difference between both groups was significantly high (p<0.0001). MCP-1 was positively correlated with disease activity, but it did not reach statistically significant value (p>0.05). Level of MCP-1 was higher in subjects with heterozygous MCP-1 and CCR2 genes (310±247.74mg/l) compared to subjects with normal MCP-1 and CCR2 genes and the difference was significantly high (p<0.0001). MCP-1 gene polymorphism was positive in 30% of cases versus 16.1% in healthy controls with (p>0.05). Heterozygous CCR2 gene was positive in 9 Behcet'sdisease patients and in 5 of the control group (p>0.05). Conclusion: MCP-1 serum level was significantly higher in BD cases in comparison to control group, in addition it was significantly high in subjects with heterozygous MCP1 and CCR2 compared to those with normal one. This could providemore understanding of BD pathogenesis and suggest new therapeutic modalities.

Keywords